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I.  INTRODUCTION
1
 
Each year since 1980, on a Friday in January, the Massachusetts 
Institute of Technology (“MIT”) has hosted the MIT Mystery Hunt.2  To 
win this competition, a team must solve a number of challenging puzzles 
whose solutions reveal where on the MIT campus to find a special coin.  
The first team to locate the coin wins the Mystery Hunt and is awarded 
the privilege of designing the next Mystery Hunt. 
In 2005, the clues of one of the puzzles, entitled “Shotgun Wedding,” 
involved 11 nucleotide sequence fragments, each approximately 1,000 
nucleotides in length.3  To solve this puzzle, it was necessary to 
understand that the fragments resulted from “shotgun sequencing,” a 
                                                 
©  2011 Andrew W. Torrance 
* Andrew W. Torrance is a Professor in the School of Law, a Research Associate at the 
Biodiversity Institute, and a Docking Faculty Scholar at the University of Kansas.  He 
received a Ph.D. in biology from Harvard University and a J.D. from Harvard Law School.  
The author would like to thank his research assistants, Dr. James McParland and Dr. 
Sparkle Ellison, for their invaluable assistance with research for this article. 
1 The author first presented his ideas about DNA copyright in November 2008 in a 
speech entitled “Synthesizing Law for Synthetic Biology,” at Biolaw 2.0:  Law at the Frontiers 
of Biology, at the University of Kansas School of Law.  Subsequently, the author presented 
his proposals regarding DNA copyright in March 2009 in “Synthetic Biology—Law and the 
Next Open Source Hardware,” at the MIT Innovation Lab, MIT Sloan School of 
Management; in May 2009 in “Synthesizing Law for Synthetic Biology,” at the OECD 
Collaborative Mechanisms for Intellectual Property Management Workshop, OECD 
Headquarters, Paris, France; in June 2009 in “Synthesizing Law for Synthetic Biology,” at 
the Biotech Summer Institute at Drake University and Pioneer Hi-Bred, Des Moines, Iowa; 
in November 2009 in “The Legal Possibilities of Synthetic Biology,” at the MIT Innovation 
Lab, MIT Sloan School of Management; in September 2010 in “Open Biological 
Innovation—From Patents to Commons to Copyright to Open Source,” at the Berkeley 
Open Innovation Forum, Berkeley Law Schools, Berkeley, California; in January 2011 in 
“Synthetic Biology Meets the Law,” at the American Association of Law Schools Annual 
Meeting, San Francisco, California; and in March 2011 in “Open Biological Innovation:  
From Patents to Commons to Copyright to Open Source,” at the Valparaiso University Law 
Review Symposium on Bioethics, Law, and Synthetic Biology, Valparaiso University 
School of Law, Valparaiso, Indiana.  The author has previously published articles about 
gene patents Andrew W. Torrance, Gene Concepts, Gene Talk, and Gene Patents, 11 MINN. J.L. 
SCI. & TECH. 157, 157–91 (2010) [hereinafter, Torrance, Gene Concepts, Gene Talk, and Gene 
Patents], and Andrew W. Torrance, Patent Rights and Civil Wrongs:  The ACLU Lawsuit, 8 
BIO-IT WORLD 11 (2009); synthetic biology, Andrew W. Torrance, Synthesizing Law for 
Synthetic Biology, 11 MINN. J.L. SCI. & TECH. 157, 642–48 (2010) [hereinafter, Torrance, 
Synthesizing Law for Synthetic Biology]; and genomics, Andrew W. Torrance, Family Law and 
the Genomic Revolution, 79 U. MO. KAN. CITY L. REV. 271 (2011) that draw on some common 
research sources. 
2 MIT Mystery Hunt, MIT.EDU, http://web.mit.edu/puzzle/www/index.html (last 
visited June 27, 2011).  Thank you to James Grimmelmann for bringing this to my attention 
on the IPProfs listserv (October 14, 2010). 
3 Jed Goldstone, Shotgun Wedding, MIT.EDU, http://web.mit.edu/puzzle/www/05/ 
setec/shotgun_wedding (last visited June 27, 2011). 
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method of determining the sequential nucleotides in a stretch of 
deoxyribonucleic acid (“DNA”).  The fragments had to be aligned 
“contiguously,” and the ends of “contig[s]” translated into their 
corresponding amino acids.  Done properly, this resulted in the 
following instruction:  “SEEKGENEFRAMES.”  Finally, the longest 
“open reading frame[ ],” when translated into its corresponding amino 
sequence, yielded the message 
“MYANSWERISSEPARATECHECKSANDTHERESTISFILLER.”4  
Armed with this clue, teams could progress to the next stage in the 
Mystery Hunt. 
An intriguing feature of the Shotgun Wedding puzzle is that the 
DNA sequences it employed were designed by Jed Goldstone not to be 
precursors for the synthesis of a polypeptide that might be useful in 
treating disease, conferring a useful trait on a crop plant, or carrying out 
an industrial process.  Rather, Goldstone simply used the genetic code of 
nucleotides adenine (“A”), guanine (“G”), thymine (“T”), and cytosine 
(“C”), and the amino acids (for example, methionine (“M”), tyrosine 
(“Y”), and alanine (“Ala”)) encoded by triplet codons of these 
nucleotides to create a short intelligible message.  Goldstone was an 
author, his medium was DNA, and his products were original and 
expressive literary works.  Although Goldstone employed A, G, T, and C 
as symbols to represent nucleotides, he might instead have chosen to 
compose his work using actual nucleotides decipherable through routine 
chemical sequencing techniques.  Either way, the original work of 
authorship that Goldstone created in a tangible medium of expression 
using sequences of nucleotides and amino acids is eligible for copyright 
protection.  In fact, even DNA sequences that code for functional 
polypeptides or RNAs may qualify for copyright protection to the extent 
that function does not dictate structure, and expression is not unduly 
constrained. 
The idea of DNA copyright is not new. 5  As long ago as 1982, Irving 
Kayton concluded that copyright protection is available for DNA.6  Since 
then, several other authors have similarly concluded that DNA 
constitutes subject matter eligible for copyright.7  However, as Rebecca 
                                                 
4 Id. 
5 In this article, the discussion explicitly focuses on the applicability of copyright law to 
DNA.  However, this discussion is also germane to RNA, a similar and related nucleic acid, 
and polypeptides, which are functionally related to both DNA and RNA. 
6 Irving Kayton, Copyright in Living Genetically Engineered Works, 50 GEO. WASH. L. REV. 
191, 191–92 (1982). 
7 Dan L. Burk, Copyrightability of Recombinant DNA Sequences, 29 JURIMETRICS J. 469, 531–
32 (1988–89); Jorge A. Goldstein, Copyrightability of Genetic Works, 2 BIO/TECHNOLOGY 138 
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Eisenberg observed in 1990, “copyright protection for DNA sequences 
has failed to make its mark outside the scholarly literature.”8  Since then, 
this situation may have begun to change. 
In 2002, an organization called the DNA Copyright Institute began to 
advertise a service involving the “copyrighting” of a person’s genome to 
guard against infringement or misappropriation by others.9  However 
unlikely it is that an existing naturally occurring genome could 
constitute a work of authorship, the idea of DNA copyright has begun to 
gain traction, especially with respect to partially or fully synthesized 
genes or other DNA sequences.10  Improvements in methods of gene 
sequencing and gene synthesis have transformed the prospect of 
designer DNA from laborious and unpredictable to routine and certain.  
Furthermore, the burgeoning field of synthetic biology is founded, at 
least in part, on the promise of deliberately engineering genes, cells, and 
organisms de novo.  In fact, the use of DNA copyright has already begun 
in industry.  Illumina, Inc., a biotechnology firm whose genome 
sequencing machines lead the genomics industry,11 produces DNA 
molecules to be used with its machines, and views their molecules as 
works of genetic authorship.  Moreover, Illumina explicitly asserts 
copyright protection over some of its DNA sequences.  To illustrate, the 
following is a letter sent to an Illumina customer: 
Dear Customer, 
This communication is in response to your request for 
particular oligonucleotide sequences for use with the 
Illumina Genome Analyzer and associated assays.  
Below please find the oligonucleotide sequences that we 
can make available to you.  This communication is solely 
for your use and should not be distributed outside your 
institution. 
                                                                                                             
(1984); Donna Smith, Comment, Copyright Protection for the Intellectual Property Rights to 
Recombinant Deoxyribonucleic Acid:  A Proposal, 19 ST. MARY’S L.J. 1083, 1096–1108 (1988). 
8 Rebecca Eisenberg, Patenting the Human Genome, 39 EMORY L.J. 721, 721 n.3 (1990). 
9 Peter Huck, How the Rich and Famous will Fight to Stay Unique, SUNDAY TRIB. (Mar. 28, 
2010), http://tribune.maithu.com/article/2001/oct/14/how-the-rich-and-famous-will-
fight-to-stay-unique/. 
10 In this article, “gene” and “DNA sequence” are often used interchangeably, where 
appropriate.  However, DNA sequences constitute the broader, more inclusive category.  
Genes fall within one particular category of DNA sequences, while there are many other 
types of DNA sequences that are not genes. 
11 See Fact Sheet, ILLUMINA.COM, http://www.illumina.com/Documents/company/ 
IlluminaCorporateSheet_050410.pdf (last visited July 17, 2011) (claiming Illumina, Inc. is a 
“leading developer, manufacturer, and marketer of life science tools and integrated 
systems for large-scale analysis of genetic variation and function.”). 
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The oligonucleotide sequences are protected by 
copyright which is owned by Illumina.  Illumina allows 
you to reproduce the oligonucleotide sequences for use 
with the Illumina Genome Analyzer and associated 
assays.  Additionally, Illumina realizes customers may 
need to make alterations to the oligonucleotide 
sequences that are necessary to allow use with the 
Illumina Genome Analyzer and associated assays.  Thus, 
Illumina allows you to make such necessary alterations 
to the oligonucleotide sequences but only for use with 
the Illumina Genome Analyzer and associated assays.  
Illumina grants you no other rights to use, reproduce or 
otherwise disclose the oligonucleotide sequences.  
Alteration or modification of the oligonucleotide 
sequences for use with non-Illumina products is not 
allowed. 
 
If you reproduce the oligonucleotide sequences for 
viewing within your institution, the following copyright 
notice must remain affixed to the sequences: 
Oligonucleotide sequences © 2006 Illumina, Inc.  
All rights reserved.  Illumina customers may 
reproduce and create derivative works of the 
oligonucleotide sequences but only for use with 
the Illumina Genome Analyzer and associated 
assays.  All other uses are strictly prohibited. 
 
If you reproduce these oligonucleotide sequences for 
viewing outside your institution (e.g. journal 
publication), you must affix the following copyright 
notice to the sequences: 
 
Oligonucleotide sequences © 2006 Illumina, Inc.  All 
rights reserved.12 
Like Goldstone, Illumina designed the oligonucleotides referenced in 
the above letter.  The nucleotide sequences of the primers and adapters 
are not copies of genomic DNA sequences; they are synthetic sequences 
                                                 
12 Letter from Illumina for Customers (Oct. 13, 2010), available at http://www.bioinfo. 
uh.edu/IMDSC/Release_of_Oligo_Sequences_Letter_for_Customers1.pdf.  Thank you to 
Jessica Sibley for bringing this to my attention on the IPProfs listserv. 
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not found in nature.13  In fact, it is probably important that they not be 
genomic DNA sequences, because, if they were, they might hybridize 
with complementary DNA sequences loaded onto Illumina sequencing 
machines. Rather, these synthetic sequences must employ designs that 
ensure their compatibility with machines sold by Illumina.  The Illumina 
customer letter indicates that the company considers its authored 
oligonucleotides to be protected by copyright.  Although these Illumina 
sequences may possess more functionality than those composed by 
Goldstone, Illumina is correct in its assumption that authored synthetic 
DNA sequences are eligible for copyright protection.14 
This Article suggests that DNA—especially synthetic DNA—
constitutes eligible subject matter for copyright protection under the 
Copyright Act.  Although DNA has long been copyrightable, in theory, 
the movement towards synthetic DNA in biotechnology has further 
strengthened existing arguments in favor of DNA copyright.  Section II 
of this Article illustrates some of the features of DNA that suit it for 
copyright protection by tracing the conceptual evolution of DNA from 
factor to program.  Section III suggests the usefulness of DNA copyright 
through a discussion of the recent rocky road down which gene patents 
have been traveling.  Section IV sketches the rise of synthetic biology as a 
distinct field.  Section V outlines why DNA is eligible for copyright 
protection, considers implications of DNA copyright, and then discusses 
benefits that might accrue to society under a DNA copyright regime, 
including those flowing from fair use provisions and the fostering of 
open source biology.  The Article concludes by suggesting that DNA 
copyright:  (1) already exists; (2) provides an alternative to DNA 
patenting; and (3) may provide a number of societal benefits in terms of 
biological innovation and improved societal access to the fruits of such 
innovation. 
II.  EVOLVING CONCEPTS OF DNA 
Few concepts in science have undergone such rapid and complete 
transformation as the concept of the unit of heredity.  At various times in 
                                                 
13 Rochelle Dreyfuss, IPProfs Listserv (Oct. 14, 2010). 
14 The United States Copyright Office appears to have acknowledged the 
copyrightability of DNA in 1987.  See J. SIGALOS, INTELLECTUAL PROPERTY PROTECTION FOR 
BIOTECHNOLOGY INNOVATIONS 13 (1987) (stating the “Copyright Office advises drawing of 
DNA nucleotide sequence bearing copyright notice sufficient for copyright”).  But see 
OFFICE OF TECH. ASSESSMENT, OTA-BA-370, NEW DEVELOPMENTS IN BIOTECHNOLOGY:  
PATENTING LIFE—SPECIAL REPORT 43 (1989) (noting that the Copyright Office’s unofficial 
position that nucleic acid sequences are not copyrightable, citing Peter R. Bahn & Steven J. 
Hultquist, Engineered Proteins as Intellectual Property, GENETIC ENGINEERING NEWS, Mar. 
1987, at 18–19). 
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history, what is often called the “gene” was believed to be a spirit, a 
liquid, or a particle.  Now, the gene is generally conceived of as a stretch 
of DNA capable of encoding information, which, in turn, is capable of 
acting as a template for constructing complementary sequences of DNA, 
RNA (directly), or polypeptides (indirectly).  Apart from some viral 
RNA genomes, genes in nature are usually composed of DNA. 
Often only a fraction of the DNA in genes encodes “exons” and is 
expressed as mRNA and by extension, polypeptide products.15  In fact, 
non-expressed DNA, or “introns,” in mammals, insects, and birds 
comprise about 80% of the nucleotide length of a gene.16  Moreover, the 
vast majority of the human genome—about 98%—does not encode 
polypeptides.17  Noncoding and apparently nonfunctional DNA has 
been dismissively termed “junk DNA.”  Much of this noncoding DNA 
may eventually be discovered to possess functionality, but it appears 
likely that much of the DNA in the genomes of humans and other 
organisms may lack direct function. 
As the understanding of DNA has evolved over the last century, so 
have the economic and legal treatments of DNA.  From the beginnings of 
the biotechnology industry in the 1970s, many have sought to attach 
intellectual property protection to DNA and related molecules.  The 
protection offered by trade secrecy depends on the extent to which the 
molecule to be protected is disclosed by the product or service of which 
it forms a part, but is agnostic about how exactly science conceives of 
that molecule.  The aptness of patent protection for DNA increased as 
the conception of genes underwent a transition from inchoate factors to 
discrete molecules.  Patent protection for DNA seemed assured in 1980 
by the landmark Supreme Court decision in Diamond v. Chakrabarty.18  
However, patent protection for DNA isolated from genomic sources has 
lately been put into doubt by the Southern District of New York’s 
decision in Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 
and remains in doubt following the Second Circuit’s ruling on the case.19  
As the conception of DNA shifted again from a mere physical molecule 
to a repository of information and instructions, copyright became a more 
                                                 
15 BENJAMIN LEWIN, GENES IX 45 (2008). 
16 Id. 
17 Greg Elgar & Tanya Vavouri, Tuning in to the Signals:  Noncoding Sequence Conservation 
in Vertebrate Genomes, 24 TRENDS GENETICS 344, 345 (2008). 
18 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
19 Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office, 702 F. Supp. 2d 181 
(S.D.N.Y. 2010) (holding that patents on DNA that indicate breast cancer susceptibility 
were invalid).  On July 29, 2011, the Federal Circuit reversed the Southern District of New 
York’s decision in part and affirmed in part.  Ass’n for Molecular Pathology v. U.S. Patent 
& Trademark Office, 2011 WL 3211513 (Fed. Cir. July 29, 2011). 
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promising source of intellectual property protection.  To understand the 
transition in intellectual property eligibility, it is important to trace how 
the conception of genes and DNA has evolved. 
A. Factor 
One of the signal achievements of Charles Darwin was the idea that 
evolution occurs by means of “descent with modification.”20  However, 
Darwin did not determine the specific mechanism by which 
modifications were passed along from ancestors to descendants.  Rather, 
as suggested by the title of his masterwork, The Origin of Species by Means 
of Natural Selection, he identified natural selection as a higher order cause 
of evolutionary change.  What Darwin did contribute was speculation 
about the existence of “gemmules” as the specific units of heredity.21 
At about the same time, an Austrian monk named Gregor Mendel 
had formed a hypothesis that plant traits were passed from parents to 
offspring by means of “Elemente.”22  Through carefully controlled 
experiments on pea plants, Mendel not only demonstrated the efficacy of 
his Elemente hypothesis, but also elucidated the basic rules of heredity.23  
Mendel’s foundational research came to prominence only after it was 
published in English in 1901.24 
Neither Darwin’s “gemmules” nor Mendel’s “Elemente” survived as 
a description of the unit of heredity.  That distinction went instead to the 
“gene,” a word coined by Wilhelm Johannsen and inspired by 
“pangens,” a word coined by Hugo de Vries.25  The word “gene” rapidly 
rose to dominance as a description of the fundamental unit of heredity. 
B. Particle 
The unit of heredity gradually underwent a transition from a vague 
factor of unknown form to a discrete and physical object.  In the 19th 
century, August Weismann proposed the existence of “determinants,” 
which he imagined to be particles of “a definite chemical, and above all, 
                                                 
20 CHARLES DARWIN, ON THE ORIGIN OF SPECIES BY MEANS OF NATURAL SELECTION 456 
(Harvard Univ. Press 1966) (1859). 
21 See EVELYN FOX KELLER, THE CENTURY OF THE GENE 2 (2000) (explaining Darwin’s 
impact on the understanding of genes). 
22 Id. at 19. 
23 See generally Gregor Mendel, Experiments in Plant Hybridisation, 26 J. ROYAL 
HORTICULTURAL SOC’Y 1 (1901) (proving that certain pairs of differentiating characters, the 
germ-cells of a hybrid, or cross-bred, are pure, being carriers and transmitters of either the 
one character or the other, not both). 
24 Id. 
25 KELLER, supra note 21, at 1–2. 
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molecular composition.”26  His views were echoed by his contemporary, 
Hugo de Vries, who insisted that “[j]ust as physics and chemistry go 
back to molecules and atoms, the biological sciences have to penetrate to 
these units in order to explain, by means of their combinations, the 
phenomena of the living world.”27  In addition to clarifying the 
mechanisms of heredity, understanding the particulate nature of 
hereditary units facilitated the growth of experimental genetics. 
In the “Fly Room” at Columbia University, Thomas Hunt Morgan 
used the fruit fly (Drosophila melanogaster) as a model organism for 
experimental genetics.28  Among other accomplishments, Morgan was 
able to demonstrate that genes reside on chromosomes, and in his book 
entitled The Theory of the Gene, he described the orientation of genes on 
chromosomes as “beads on a string.”29  Due largely to Morgan, whose 
research won him the 1933 Nobel Prize in Medicine, “genes became 
generally viewed as discrete, stable, independently segregating units of 
inheritance lined up along a chromosome, an image captured by the 
most commonly invoked metaphor—that of ‘beads on a string.’”30  
However, if they can be viewed as particles, genes are very peculiar 
particles that encode remarkable amounts of information. 
C. Molecule 
By the middle of the 20th century, the idea that genes consisted of 
discrete particles had become firmly entrenched in biology.  However, 
the precise structural and functional nature of these particles had not yet 
been elucidated.  Both polypeptides and nucleic acids, such as DNA, had 
been proposed as the carriers and determinants of hereditary traits. The 
scales tipped decisively in favor of DNA following the Avery-MacLeod-
McCarty experiment.  In 1943, two Canadians, Oswald Avery and Colin 
MacLeod, and an American, Maclyn McCarty, experimentally 
determined that bacterial genes were composed of DNA, which “must 
be regarded not merely as structurally important but as functionally 
active in determining the biochemical activities and specific 
                                                 
26 August Weismann, The Continuity of the Germ-Plasm as the Foundation of a Theory of 
Heredity, in ESSAYS UPON HEREDITY AND KINDRED BIOLOGICAL PROBLEMS 167, 168 (Edward 
B. Poulton et al. eds., 1891). 
27 HUGO DE VRIES, INTRACELLULAR PANGENESIS 13 (C. Stuart Gager trans., The Open 
Court Publishing Co. 1910) (1889). 
28 See JAMES D. WATSON ET AL., MOLECULAR BIOLOGY OF THE GENE 12–14 (Beth Wilbur et 
al. eds., 6th ed. 2008). 
29 THOMAS HUNT MORGAN, THE THEORY OF THE GENE 24 (1928). 
30 Leonie Moyle, Most Ingenious:  Troubles and Triumphs of the Century of Genes, 17 
BIOLOGY & PHIL. 715, 715–16 (2002). 
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characteristics of pneumococcal cells.”31  Alfred Hershey and Martha 
Chase later confirmed this discovery in blender experiments using 
bacteria and bacteriophage.32  The vague concept of a gene as a physical 
particle had been married to a specific molecule:  DNA. 
D. Sequence 
In 1953, James Watson and Francis Crick announced that they had 
discovered the physical conformation of DNA:  two individual DNA 
molecules wind around each other in antiparallel to form a double 
helix.33  As Watson and Crick explained: 
In the double helix, the two DNA chains are held 
together by hydrogen bonds . . . between pairs of bases 
on the opposing strands . . . .  This base pairing is very 
specific:  the purine adenine only base-pairs to the 
pyrimidine thymine, whereas the purine guanine only 
base-pairs to the pyrimidine cytosine.  In double-helical 
DNA, the number of A residues must be equal to the 
number of T residues, whereas the number of G and C 
residues must likewise be equal . . . .  As a result, the 
sequence of the bases of the two chains of a given double 
helix have a complementary relationship, and the 
sequence of any DNA strand exactly defines that of its 
partner strand.34 
This announcement “convinced biologists not only that genes are real 
molecules but also that they are constituted of nothing more mysterious 
than deoxyribonucleic acid.”35  Building on the insight of the double 
helix, Seymour Benzer was soon able to demonstrate that genes were 
linear stretches of DNA sequence.36  
Once DNA had been understood to comprise linear arrays of 
nucleotides, much research was devoted to determining the exact 
nucleotide sequences of DNA molecules of interest.  At first, these efforts 
were laborious and inefficient.  Early sequencing efforts relied on 
restriction enzymes, which are proteins capable of snipping a DNA 
                                                 
31 Oswald T. Avery et al., Studies on the Chemical Nature of the Substance Inducing 
Transformation of Pneumococcal Types, 79 J. EXPERIMENTAL MED. 137, 155 (1944). 
32 See generally A. D. Hershey & Martha Chase, Independent Functions of Viral Proteins and 
Nucleic Acid in Growth of Bacteriophage, 36 J. GEN. PHYSIOLOGY 39 (1952). 
33 WATSON ET AL., supra note 28, at 22. 
34 Id. 
35 KELLER, supra note 21, at 3. 
36 Id. at 52. 
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molecule at sites characterized by specific patterns of nucleotides.  
Restriction enzymes can be employed to recognize locations in the 
genome hosting particular nucleotide motifs.37  However, by the 1970’s, 
sequencing methods had improved so substantially that one could 
identify the precise pattern of individual nucleotides in a DNA molecule.  
These methods worked as follows: 
The underlying principle of DNA sequencing is based 
on the separation, by size, of nested sets of DNA 
molecules.  Each of the DNA molecules starts at a 
common 5' end, and terminates at one of several 
alternative 3' endpoints.  Members of any given set have 
a particular type of base at their 3' ends.  Thus, for one 
set, the molecules all end with a G, for another a C, for a 
third an A, and for the final set a T.  Molecules within a 
given set (e.g., the G set) vary in length depending on 
where the particular G at their 3' end lies in the 
sequence.  Each fragment from this set therefore 
indicates where there is a G in the DNA molecule from 
which they were generated.38 
Allan Maxam and Walter Gilbert invented one of the leading methods, 
known as “Maxam-Gilbert sequencing,” which used “four different 
regimens of chemical treatment that cause [radiolabeled DNA molecules] 
to break preferentially at Gs, Cs, Ts, or As.”39  Frederick Sanger invented 
the other leading method, called the “[Sanger] chain-termination 
method,” which used the enzyme DNA polymerase to create 
complementary copies of fragments of the DNA molecule being 
sequenced.40  Gilbert and Sanger shared the 1980 Nobel Prize in 
chemistry “for their contributions concerning the determination of base 
sequences in nucleic acids.”41  Further improvements in sequencing have 
made the determination of DNA sequences from all biological sources 
routine.  Even entire genomes, such as those of humans, have been 
                                                 
37 ANTHONY J. F. GRIFFITHS ET AL., INTRODUCTION TO GENETIC ANALYSIS 343–60 (2005). 
38 WATSON ET AL., supra note 28, at 753. 
39 Id. at 754; see Allan M. Maxam & Walter Gilbert, A New Method for Sequencing DNA, 74 
PROC. NAT’L ACAD. SCI. U.S.A. 560 (1977). 
40 WATSON ET AL., supra note 28, at 754. 
41 See Bo G. Malmstrom, The Nobel Prize for Chemistry (1980), in NOBEL LECTURES:  
CHEMISTRY 377–432 (Tore Frängsmyr & Sture Forsén 1980). 
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sequenced.42  Consequently, the total amount of known DNA sequence 
information forms an ever growing mountain of data. 
E. Information 
Long before the discovery of the DNA double helix, Archibold 
Garrod suggested that “genes work by controlling the synthesis of 
specific enzymes.”43  Employing Neurospora fungus as a model organism, 
George Beadle and Edward Tatum were able to confirm this “[O]ne 
[G]ene-[O]ne [E]nzyme [H]ypothesis” by demonstrating that “one gene 
controlled a single chemical reaction, which in turn was regulated by a 
specific enzyme.”44  This led to the parsimonious inference that “genetic 
information within genes determines the order of the 20 different amino 
acids within the polypeptide chains of proteins.” 45 
Close on the heels of announcing the DNA double helix, Watson and 
Crick published the “Genetical Implications of the Structure of 
Deoxyribonucleic Acid,” in which they postulated that the DNA 
sequence of a gene corresponded precisely to the amino acid sequence of 
a corresponding polypeptide.46  In 1958, Crick elaborated on this 
hypothesis, proposing that “the specificity of a piece of nucleic acid is 
expressed solely by the sequence of its bases, and that this sequence is a 
(simple) code for the amino acid sequence of a particular protein.”47 
The first to crack part of the genetic code were Marshall Nirenberg 
and Heinrich Matthaei, who “observed in 1961 that the addition of the 
synthetic polynucleotide poly U (UUUUU . . . ) to a cell-free system 
capable of making proteins leads to the synthesis of polypeptide chains 
containing only the amino acid phenylalanine.  The nucleotide groups 
UUU thus must specify phenylalanine.”48  This discovery set off a race to 
break the rest of the genetic code, and “[b]y 1967 the code was essentially 
completed.”49  Understanding DNA as encoding information via a 
specific language of codons revealed a duality in the nature of genes and 
DNA:  they were simultaneously physical and informational.  The 
                                                 
42 See, e.g., E. S. Lander et al., Initial Sequencing and Analysis of the Human Genome, 409 
NATURE 860 (2001); J. Craig Venter et al., The Sequence of the Human Genome, 291 SCI. 1304 
(2001). 
43 WATSON ET AL., supra note 28, at 19. 
44 LILY E. KAY, WHO WROTE THE BOOK OF LIFE 52 (2000). 
45 WATSON ET AL., supra note 28, at 19. 
46 J. D. Watson & F. H. C. Crick, Genetical Implications of the Structure of Deoxyribonucleic 
Acid, 171 NATURE 964, 964 (1953). 
47 F. H. C. Crick, On Protein Synthesis, 12 SYMP. SOC’Y FOR EXPERIMENTAL BIOLOGY 138, 
152 (1958) [hereinafter On Protein Synthesis]. 
48 WATSON ET AL., supra note 28, at 37. 
49 KAY, supra note 44, at 330. 
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informational nature of DNA separates it qualitatively from other 
molecules.  Consequently, “[t]he human genome is now generally 
viewed as an information system and, more specifically, as a ‘Book of 
Life’ written in the language of DNA, or DNA code, to be read and 
edited.”50 
F. Program 
In his famous summation of genetics, Crick once remarked that 
“DNA makes RNA, RNA makes protein, and proteins make us.”51  
Elaborating on this simple recipe, François Jacob and Jacques Monod 
suggested that “the genome contains not only a series of blue-prints, but 
a co-ordinated program of protein synthesis and the means of 
controlling its execution.”52  Jacob and Monod uncovered a complex 
network of interacting genetic elements that came to be known as the 
“operon” model of gene regulation.53  This operon model suggested a 
“genetic program,” comprising, as it did, “a linked cluster of regulatory 
elements and structural genes whose expression is coordinated by the 
product of a regulator gene situated elsewhere in the genome.”54 
James Bonner expanded on the concept of a genetic program in his 
1965 book entitled The Molecular Biology of Development.  Bonner 
deliberately drew a close analogy between computers and cells.  He 
described a hierarchy of programs, including a “‘master programme 
constituted in turn of a set of subprogrammes or subroutines,’”55 with 
the latter further subdivided into “a list of cellular instructions or 
commands.”56 
Although organisms and their cells are not electronic computers, and 
genes are not written in software code, the similarities are striking.  In 
fact, one of the major goals of synthetic biology is “to create a 
programmable microorganism from scratch.”57 
                                                 
50 Id. at 1. 
51 KELLER, supra note 21, at 54. 
52 François Jacob & Jacques Monod, Genetic Regulatory Mechanisms in the Synthesis of 
Proteins, 3 J. MOLECULAR BIOLOGY 318, 354 (1961). 
53 See LEWIN, supra note 15, at 858 (“An operon is a unit of bacterial gene expression and 
regulation, including structural genes and control elements in DNA recognized by 
regulator gene product(s).”). 
54 KAY, supra note 44, at 57. 
55 Id. at 85, 134. 
56 Id. at 85–86. 
57 Arjun Bhutkar, Synthetic Biology:  Navigating the Challenges Ahead, 8 J. BIOLAW & BUS. 
19, 20 (2005). 
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III.  PATENT PROTECTION FOR DNA 
A. Origin 
During 1973 and 1974, Stanley Cohen and Herbert Boyer invented a 
method for removing a specific fragment of DNA from one organism 
and introducing it into the genome of a different organism.58  
Significantly, they received a patent for their invention, which was 
entitled “Process for producing biologically functional molecular 
chimeras.”59  This method proved to be important to modern molecular 
biology and foundational to the biotechnology industry.  Within several 
years, biologists had genetically engineered the eubacterium, Escherichia 
coli, successfully to express the gene encoding the human hormone 
somatostatin.60  Of similar importance to the development of the 
biotechnology industry was a legal decision about a patent application 
filed by Dr. Ananda Chakrabarty in 1972.  Rather than claim a method, 
this patent application involved a genetically modified organism.  
Among other inventions claimed in the patent application was a 
“human-made, genetically engineered bacterium . . . capable of breaking 
down multiple components of . . . oil.”61  In 1980, the United States 
Supreme Court upheld the patentability of “[a] bacterium from the 
genus Pseudomonas containing therein at least two stable energy-
generating plasmids.”62  Not only did the Supreme Court appear to 
support the patentability of organisms, it also appeared to approve of the 
patentability of isolated DNA.  Biotechnology began advancing rapidly 
on both scientific and legal fronts. 
Complex biological molecules—such as DNA, RNA, and 
polypeptides—became the subject of patent claims beginning in the early 
1970s.  Previously, patents had successfully claimed methods that 
involved polypeptides and proteins, but in 1971, composition claims 
were issued for a polypeptide in U.S. Patent Number 3,607,370,63 and for 
a protein in U.S. Patent Number 3,619,206.64  Additionally, in 1972, a 
composition claim for a peptide was issued in U.S. Patent Number 
                                                 
58 Sally Smith Hughes, Making Dollars Out of DNA—The First Major Patent in 
Biotechnology and the Commercialization of Molecular Biology, 1974–1980, 92 ISIS 541, 541 
(2001). 
59 U.S. Patent No. 4,237,224 (filed Nov. 4, 1974). 
60 Keiichi Itakura et al., Expression in Escherischia Coli of a Chemically Synthesized Gene for 
the Hormone Somatostatin, 198 SCI. 1056 (1977). 
61 Diamond v. Chakrabarty, 447 U.S. 303, 305 (1980). 
62 U.S. Patent No. 4,259,444 (filed June 7, 1972) (emphasis added). 
63 Pressure-Sensitive Adhesive Tape Comprising Gluten Hydrolypate Derivatives, U.S. 
Patent No. 3,607,370 (filed May 29, 1969). 
64 Modified Proteins, U.S. Patent No. 3,619,206 (filed May 21, 1969). 
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3,645,689.65  A similar progression occurred for DNA and genes.  A 
patent claim including “DNA” was issued in 1973,66 the word “gene” 
occurred in an issued claim in U.S. Patent Number 3,710,511,67 and 1978 
saw the issuance of claims in U.S. Patent Number 4,116,770 that were 
directed to phenotypic traits encoded by specific genes.68  However, it 
was not until two years after the decision in Diamond v. Chakrabarty that 
U.S. Patent Number 4,363,877 was issued with composition claims that 
included genes, in this case encoding growth hormone polypeptide.69  
These claims were the first to cover genes themselves,70 which encoded 
“[h]uman chorionic somatomammotropin” and “the growth hormone of 
an animal species.”71 
After the Diamond v. Chakrabarty decision in 1980, patent 
applications, with a necessary lag time, issued patents claiming genes 
and DNA rose rapidly.  Annual filings of patent applications rose from 
hundreds in 1984 to thousands from the mid-1990s to the early 2000s.72  
Annual patent issuances rose from hundreds in the late 1980s to 
thousands during the late 1990s until the late 2000s.73 
B. Effect 
Patent protection affords patent owners the right to exclude others 
from making, using, offering to sell, or selling patented genes within the 
United States.  In addition, patent owners can prevent others from 
importing patented genes into the United States.74  The availability of 
patent protection for DNA sequences has played a key role in attracting 
investment to the biotechnology industry.  In fact, for an industry that 
has yet to produce a profit as a whole, patent portfolios covering genes 
may constitute one of the most valuable assets owned by biotechnology 
                                                 
65 Method and Apparatus for Analyzing Proteins, U.S. Patent No. 3,645,689 (filed Apr. 9, 
1970). 
66 Diagnostic Method Utilizing Synthetic Deoxyrilionucleotide Oligomer Template, U.S. 
Patent No. 3,755,086 (filed Feb. 9, 1971). 
67 Procedures for Use of Genic Male Sterility in Production of Commercial Hybrid 
Maize, U.S. Patent No. 3,710,511 (filed Apr. 21, 1971). 
68 Waxy Barley Starch with Unique Self-Liquifying Properties, U.S. Patent No. 4,116,770 
(filed Feb. 27, 1975). 
69 Recombinant DNA Transfer Vectors, U.S. Patent No. 4,363,877 (filed Apr. 19, 1978). 
70 Gene Patents and Global Competition Issues—Protection of Biotechnology Under Patent Law, 
GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (Jan. 1, 2006), http://www.genengnews. 
com/articles/chitem.aspx?aid=1163&chid=0. 
71 Recombinant DNA Transfer Vectors, U.S. Patent No. 4,363,877 (filed Apr. 19, 1978). 
72 Torrance, Gene Concepts, Gene Talk, and Gene Patents, supra note 1, at 157–91. 
73 Id. 
74 35 U.S.C. § 271(a) (2006). 
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companies.75  Sheila Jasanoff has described various important ways in 
which patents have supported the development of biotechnology: 
Especially in the United States, patents played a 
foundational role in the development of the 
biotechnology industry at several levels.  First, the 
extension of patents to the life sciences created new 
classes of property rights in things that were previously 
outside the realm of what could be owned, or even 
thought of as subject to ownership claims.  As a result, 
these objects became commodities that could have value, 
be exchanged, circulate in markets, and foster 
productivity.  Second, much of the early development of 
biotechnology occurred before there were any 
marketable products, and patents were the only 
evidence for eager venture capitalists that there might be 
something of future value to justify present investment.  
Third, patents provided some assurance to jittery 
investors that they would not be mired in endless legal 
wrangling if commercially useful products ever came on 
line.  Fourth, patents proved to be a way of sorting out 
the competing claims of participants in an increasingly 
complex web of invention that linked together the 
disparate interests of patients, research subjects, farmers, 
academic researchers, universities, start-up firms, 
government, and industry.76 
In short, patents appear to have played an especially crucial role in 
justifying the huge investments in research, development, and 
regulatory compliance that biotechnology and pharmaceutical 
companies face in discovering gene-based drugs and bringing them to 
market.77 
                                                 
75 See John Golden, Biotechnology, Technology Policy, and Patentability:  Natural Products 
and Invention in the American System, 50 EMORY L.J. 101 (2001). 
76 SHEILA JASANOFF, DESIGNS ON NATURE:  SCIENCE AND DEMOCRACY IN EUROPE AND THE 
UNITED STATES 203–04 (2005). 
77 In their recent study of the role that the patent system plays in spurring innovation, 
James Bessen and Michael J. Meurer suggest the patent system may indeed promote 
innovation in the pharmaceutical/biotechnology industry.  JAMES BESSEN & MICHAEL J. 
MEURER, PATENT FAILURE:  HOW JUDGES, BUREAUCRATS, AND LAWYERS PUT INNOVATORS AT 
RISK 85–88 (2008).  As Bessen and Meurer stated, “[t]he evidence certainly is consistent with 
the notion that patents encourage American pharmaceutical R&D.”  James Bessen & 
Michael J. Meurer, Do Patents Stimulate R&D Investment and Promote Growth?, PATENTLYO 
BLOG (Mar. 13, 2008), http://www.patentlyo.com/patent/2008/03/do-patents-stim.html. 
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C. Criticism 
Gene patents are not without their critics.  Controversy over 
patenting DNA is due, in large part, to the fact that even human genes 
have been considered eligible for patentable protection.  According to a 
study by Fiona Murray and Kyle Jensen, approximately 20% of the 
known genes in the human genome have been claimed in patents issued 
by the United States Patent and Trademark Office (“USPTO”).78  The 
ethics of allowing this “‘gold rush’” have been questioned,79 as have the 
practical threats to genetic research allegedly posed by the consequent 
tragedy of the “[a]nticommons.”80  More sensational claims misinterpret 
the scope of the patent grant, which, in the case of DNA derived from 
genomic sources, usually extends only to “isolated” or “purified” DNA.  
Nevertheless, Devanand Crease and George Schlich have warned that, 
“[t]o the person in the street, the grant of a patent covering all potential 
uses of these genes raises the visceral fear of corporate interests claiming 
ownership over our very bodies!,”81 while Michael Crichton raised this 
2007 alarm in the New York Times:  “YOU, or someone you love, may 
die because of a gene patent . . . .  Gene patents are now used to halt 
research, prevent medical testing and keep vital information from you 
and your doctor.”82   
Despite the sincerity of these anxieties, the data appears to tell a 
different story.  In a comprehensive analysis of all human gene patents 
identified by Murray and Jensen, Chris Holman found that “not one of 
the 4,270 patents in the dataset has ever been found to have been 
infringed or been the basis of a preliminary injunction.”83  Nevertheless, 
anxieties over the patenting of DNA appear to have struck a chord with 
judges and politicians, and the last several years have presented a 
decidedly more hostile atmosphere for DNA patents.  Three specific 
events exemplify this shift:  (1) In re Fisher, (2) the Genomic Research and 
                                                 
78 Kyle Jensen & Fiona Murray, Intellectual Property Landscape of the Human Genome, 310 
SCI. 239 (2005). 
79 Tom Hollon, Gene Patent Revisions to Remove Some Controversies, 6 NATURE MED. 362 
(2000). 
80 Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The 
Anticommons in Biomedical Research, 280 SCI. 698 (1998). 
81 Devanand Crease & George Schlich, Is There a Future for ‘Speculative’ Gene Patents in 
Europe?, 2 NATURE REVS. DRUG DISCOVERY 407 (2003) (addressing patents claiming the 
human genes, BRCA1 and BRCA2, owned by Myriad Genetics, and used to diagnose 
propensity for developing breast cancer). 
82 Michael Crichton, Op-Ed., Patenting Life, N.Y. TIMES, Feb. 13, 2007, at A2. 
83 Christopher M. Holman, The Impact of Human Gene Patents on Innovation & Access:  A 
Survey of Human Gene Patent Litigation, 76 U. MO. KAN. CITY L. REV. 295, 353–54 (2007) 
(emphasis omitted) (citations omitted). 
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Accessibility Act (“GRAA”), and (3) Ass’n for Molecular Pathology v. U.S. 
Patent & Trademark Office. 
D. Response 
In 2005, the Court of Appeals for the Federal Circuit heard an appeal 
regarding the patentability of fragments of genes called “expressed 
sequence tags” (“ESTs”), which are capable of identifying specific DNA 
sequences in maize genes.84  The Federal Circuit decided that claims to 
these ESTs were invalid because they lacked utility and enablement.  In 
explaining its decision, the court argued that: 
The basic quid pro quo contemplated by the 
Constitution and the Congress for granting a patent 
monopoly is the benefit derived by the public from an 
invention with substantial utility.  Unless and until a 
process is refined and developed to this point—where 
specific benefit exists in currently available form—there 
is insufficient justification for permitting an applicant to 
engross what may prove to be a broad field.85 
Rather than providing a mere benefit in conducting further research, the 
court suggested that a claimed invention should provide “some 
immediate benefit to the public” in order to be patentable.86  In the wake 
of In re Fisher, there was significant uncertainty about what 
characteristics, if any, might make a DNA fragment eligible for 
patentability.  This doubt spread to the patentability of longer stretches 
of DNA, including whole genes. 
On February 7, 2007, two members of the House of Representatives, 
Xavier Becerra (Democrat of California) and Dave Weldon (Republican 
of Florida), introduced a bill that would “end[ ] the practice of gene 
patenting [including all] genetic material, naturally-occurring or 
modified.”87  The bill, the GRAA, would amend the Patent Act by adding 
a new section specifically addressing DNA patents.  Proposed Section 
106 would end the patentability of genes and other DNA sequences by 
providing that “[n]otwithstanding any other provision of law, no patent 
may be obtained for a nucleotide sequence, or its functions or 
correlations, or the naturally occurring products it specifies.”  Soon after 
its introduction in the House, the GRAA attracted the attention of the 
                                                 
84 In re Fisher, 421 F.3d 1365, 1367 (Fed. Cir. 2005). 
85 Id. at 1371 (emphasis omitted). 
86 Id. (emphasis omitted) (citation omitted). 
87 153 CONG. REC. E315–16 (daily ed. Feb. 9, 2007) (statement of Rep. Xavier Becerra). 
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Subcommittee on Courts, the Internet and Intellectual Property. A 
hearing called “Stifling or Stimulating:  The Role of Gene Patents in 
Research and Genetic Testing” was held on October 30, 2007.  The 
outlook for passage of the GRAA is uncertain.  It has not been passed by 
either the House or the Senate, and one of its sponsors, Representative 
Weldon, is no longer a member of the House. 
However, the aims of the GRAA are strikingly congruent to the 
results of Ass’n for Molecular Pathology v. U.S. Patent & Trademark Office.  
In fact, the decision by Judge Sweet in Ass’n for Molecular Pathology v. 
U.S. Patent & Trademark Office appeared to echo Becerra’s assessment of 
the patent requirement that DNA must be “isolated and purified” as 
“mere wordplay.”88  Sweet similarly described this requirement as a 
“lawyer's trick.”89  Furthermore, a proposed last-minute amendment to 
the Patent Reform Act of 2011 would have created Section 287(d) to 
create a safe harbor provision to limit infringement remedies against 
anyone who performs a genetic diagnostic test to give a patient a second 
opinion.90  The American Civil Liberties Union (“ACLU”) and its allies 
opposed this amendment, fearing that it “would fail to block all patent 
holder objections to such testing, fails to address the many other 
limitations on scientific research arising out of the issuance of such 
patents, and risks allowing gene patent holders to argue that Congress 
implicitly endorses the validity of such patents.”91  Although the 
amendment was subsequently withdrawn, it resurfaced in the patent 
reform bill that passed the House on June 23, 2011.92  Obviously, there 
continues to be significant Congressional interest in curtailing patents 
that claim DNA sequences.  
The most important event thus far in darkening the prospects for 
DNA patents began on May 12, 2009.  The ACLU represented several 
female patients as well as a number of sympathetic organizations.  
Together, they sued the USPTO, a Utah-based biotechnology firm called 
Myriad Genetics, and the Directors of the University of Utah Research 
Foundation in the Federal court for the Southern District of New York.  
                                                 
88 Id. 
89 Ass’n for Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 
2010). 
90 Amendment to America Invents Act of 2011, H.R. 1249, 112th Cong. (1st Sess. 2011). 
91 Letter from Laura W. Murphy, Dir., Washington Legislative Office, to Chairman 
David Dreier, Comm. on Rules, U.S. House of Representatives (June 15, 2011) (on file with 
the ACLU). 
92 America Invents Act of 2011, H.R. 1249, 112th Cong. (1st Sess. 2011).  This bill was 
subsequently enacted into law.  Leahy-Smith America Invests Act.  Pub. L. No. 112-29, 125 
Stat. 284. 
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The cause of action in the lawsuit was opposition to the patenting of 
human genes and diagnostic uses thereof.93  The complaint stated: 
Every person’s body contains human genes, passed 
down to each individual from his or her parents. These 
genes determine, in part, the structure and function of 
every human body. This case challenges the legality and 
constitutionality of granting patents over this most basic 
element of every person’s individuality. . . . [as well as 
granting patents covering] the concept of looking at or 
comparing human genes, and correlations found in 
nature between certain genes and an increased risk of 
breast and/or ovarian cancer. . . .94 
In addition to attracting wide publicity, the ACLU lawsuit surprised 
many when it was taken seriously by the court. 
The ACLU argued that the patent eligibility of genes posed a direct 
and serious threat to those susceptible to breast and ovarian cancers.  
Breast cancer afflicts about 13% of women in the United States over their 
lifetimes, is newly diagnosed in roughly 200,000 women annually, and is 
responsible for about 40,000 deaths per year, making it the third largest 
cause of cancer deaths.95  The lifetime risk of developing ovarian cancer 
is about 1.7%.  However, for carriers of the BRCA (“breast cancer”) 
tumor suppressor gene mutations 1 (“BRCA1”) and 2 (“BRCA2”), the 
lifetime probability of developing breast cancer and ovarian cancer rises 
dramatically to 36–85% and 20–60%, respectively.96  Although knowing 
that one has BRCA1 or BRCA2 mutations is terrible news, it does allow 
the carrier and her physician to attempt to minimize other risks of 
developing cancer.  As a result, Myriad Genetics has become a profitable 
company by acquiring patents covering both the BRCA1 and BRCA2 
mutations and offering genetic tests to detect the presence of these 
mutations.97  The ACLU argued that it is immoral to allow Myriad 
                                                 
93 Complaint at 1, 3, Ass’n for Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 
181 (S.D.N.Y 2010) (No. 2010-1406). 
94 Id. 
95 Breast Cancer, MAYO CLINIC (2011), http://www.mayoclinic.org/breast-cancer/. 
96 NORTHWESTERN ASSOCIATION FOR BIOMEDICAL RESEARCH, APPENDIX A2, available at 
http://nwabr.org/sites/default/files/learn/bioinformatics/IntroAppendix.pdf (last 
visited Oct. 26, 2011); see also Matthew J. Piehl, The Brave New World of Genetic Biobanks:  
International Lessons for a Potential United States Biobank, 46 VAL. U. L. REV. 69, 93–94 (2011) 
(describing the harmful effects of the BRCA1 and BRCA2 gene mutations and a woman’s 
right not to know she is carrying them). 
97 See ENCYCLOPEDIA OF SCIENCE AND TECHNOLOGY COMMUNICATION 331 (Susanna 
Hornig Priest ed., 2010) (“The patents offer Myriad Genetics exclusive rights over the 
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Genetics to restrict access to such a beneficial diagnostic test by means of 
its patents.  Myriad Genetics counter-argued that gene patents drove 
innovation into diagnostic tests, such as those it offered, by allowing 
companies a return on their investments in research, development, and 
regulatory approval. 
The district court handed ACLU a decisive victory on March 29, 
2010.  On summary judgment, Judge Sweet held that neither genes nor 
genetic tests were eligible for patent protection.  In a vigorously worded 
opinion, he undermined thirty years of DNA patent practice: 
The claims-in-suit directed to “isolated DNA” 
containing human BRCA1/2 gene sequences reflect the 
USPTO's practice of granting patents on DNA sequences 
so long as those sequences are claimed in the form of 
“isolated DNA.” This practice is premised on the view 
that DNA should be treated no differently from any 
other chemical compound, and that its purification from 
the body, using well-known techniques, renders it 
patentable by transforming it into something distinctly 
different in character. Many, however, including 
scientists in the field of molecular biology and genomics, 
have considered this practice a “lawyer's trick” that 
circumvents the prohibitions on the direct patenting of 
DNA in our bodies but which, in practice, reaches the 
same result . . . . It is concluded that DNA's existence in 
an “isolated” form alters neither this fundamental 
quality of DNA as it exists in the body nor the 
information it encodes. Therefore, the patents at issue 
directed to “isolated DNA” containing sequences found 
in nature are unsustainable as a matter of law and are 
deemed unpatentable subject matter under 35 USC 
§ 101.98 
Myriad Genetics promptly appealed this summary judgment decision to 
the Federal Circuit.  Fearing massive losses if their vast portfolios of 
DNA patents were also found invalid, the pharmaceutical and 
biotechnology industries strongly supported the appeal. 
                                                                                                             
BRCA1 and BRCA2 genes and prevent others from further studying these genes without 
getting a license and paying royalties.  Myriad established a monopoly for the genetic test, 
and currently there is no other way to test for the presence of BRCA mutations without 
infringing the Myriad patent.”). 
98 Ass’n for Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 
2010). 
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Before the Federal Circuit ruled on the appeal, one of the original 
defendants, the United States (representing the USPTO), surprised 
supporters and opponents of Myriad Genetics alike when it changed 
sides to support, at least partially, positions of the ACLU.  On October 
29, 2010, the Department of Justice filed an amicus curiae brief on behalf 
of the federal government—including erstwhile defendant, the USPTO—
arguing that “isolated but otherwise unaltered” human genes constitute 
unpatentable subject matter because they are products of nature under 
35 U.S.C. § 101.99  On July 29, 2011, a panel of three Federal Circuit 
judges reversed much of Judge Sweet’s decision, and, in doing so, 
reaffirmed the eligibility of isolated DNA sequences for patent 
protection.100  Notwithstanding this latest change of fortunes for gene 
patents, it is likely that the losing party, the Association for Molecular 
Pathology, will appeal this decision to the United States Supreme Court.  
If the Supreme Court does grant a writ of certiorari in this case, perhaps 
pairing it with another case, Prometheus v. Mayo,101 in which it already 
granted certiorari to consider the patent-eligibility of biotechnology 
inventions, and given the new official position of the federal 
government, a decision finding at least some categories of DNA 
ineligible for patenting is possible. 
The results of the recent trend to limit patents claiming DNA will not 
be known until two things happen:  the federal courts finally decide the 
issues in Ass’n for Molecular Pathology v. Myriad Genetics and Prometheus v. 
Mayo, and Congress finally decides on what, if any, statutory reforms it 
supports.  In the meantime, much uncertainty hovers over the future 
viability, vitality, and value of DNA patents.  Copyright protection for 
DNA sequences offers an alternative. 
IV.  SYNTHETIC BIOLOGY 
In its most optimistic conception, the field of synthetic biology 
promises nothing short of a brave new world.  As Michael Specter 
observed in 2009, “[i]f the science truly succeeds, it will make it possible 
to supplant the world created by Darwinian evolution with one created 
by us.”102  However, the field has more modest immediate goals:  “By 
                                                 
99 Brief for the United States as Amicus Curiae in Support of Neither Party, Ass’n for 
Molecular Pathology v. Myriad Genetics, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) (No. 2010-
1406). 
100 Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 653 F.3d 1329 
(Fed. Cir. 2011). 
101 Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347 (Fed. Cir. 2010). 
102 Michael Specter, A Life of Its Own:  Where Will Synthetic Biology Lead Us?, THE NEW 
YORKER, Sept. 28, 2009, at 57. 
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using gene-sequence information and synthetic DNA, they are 
attempting to reconfigure the metabolic pathways of cells to perform 
entirely new functions, such as manufacturing chemicals and drugs.  
Eventually, they intend to construct genes—and new forms of life—from 
scratch.”103  The success of synthetic biology will largely depend on two 
fundamental technologies whose very names suggest the relevance of 
copyright:  (1) reading DNA (via rapid and inexpensive sequencing); and 
(2) writing DNA (via rapid and inexpensive synthesis).  To the long 
evolution of DNA concepts, from factor to particle to sequence to 
information to program, synthetic biology has the added possibility of 
viewing DNA as lego-like “BioBricks” that can be arranged and 
rearranged at will to build new structures and functions.  In addition, 
synthetic biology has introduced the idea of biologists as creative 
authors engaged in literally writing the future of the book of life 
nucleotide by nucleotide. 
A. Recombining 
The methods of recombinant DNA developed by Cohen and Boyer 
demonstrated that DNA from a foreign source organism could be 
reliably spliced into the genome of a distinct host organism.  They used 
restriction endonucleases to create a gap in a eubacterial plasmid, 
inserted foreign DNA into the gap, and used DNA ligase to splice the 
plasmid and foreign DNA together.104  By showing that DNA could be 
recombined into arrangements not found in existing genomes,105 Cohen 
and Boyer opened the door to the deliberate design of new genomes.  
The subsequent successful insertion of the human somatostatin gene into 
a eubacterial genome amplified this possibility by demonstrating the 
intercompatibility of DNA from very disparate phylogenetic sources.106  
These experiments and techniques heralded “the new era of ‘synthetic 
biology’ where not only existing genes are described and analyzed but 
also new gene arrangements can be constructed and evaluated.”107 
B. Programming 
Biologists have long used the metaphor of the computer program to 
describe the function of DNA.  Crick’s succinct formulation anticipated 
                                                 
103 Id. at 56 (emphasis added). 
104 Stanley N. Cohen et al., Construction of Biologically Functional Bacterial Plasmids In Vitro, 
70 PROC. NAT’L ACAD. SCI. 3240, 3240 (1973). 
105 Id. at 3244. 
106 E.g., Itakura et al., supra note 60, at 1056. 
107 Waclaw Szybalski & Ann Skalka, Nobel Prizes and Restriction Enzymes, 4 GENE 181, 
181–82 (1978). 
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subsequent, more explicit, uses of the metaphor:  “DNA makes RNA, 
RNA makes protein, and proteins make us.”108  Jacob and Monod offered 
a more direct formulation, suggesting that “the genome contains not 
only a series of blue-prints, but a co-ordinated program of protein 
synthesis and the means of controlling its execution.”109  Bonner 
completed the progression by describing the genome as a “master 
programme constituted in turn of a set of subprogrammes or 
subroutines.”110  To be accurate, these formulations of DNA as computer 
programs depend on cells or organisms capable of reliably processing 
and implementing the instructions of their DNA programs.  While 
natural organisms that have resulted from organic evolution may 
present challenges in this regard, a goal of synthetic biology is to 
introduce reliability and predictability through deliberate and careful 
engineering.  To this end, Arjun Bhutkar asserts that “[a] primary 
objective of this nascent research area is to create a programmable 
microorganism from scratch.”111 
C. Engineering 
What is currently called synthetic biology was once known as 
biological engineering.  In the 1930s, MIT appointed Professor Joseph 
Warren Horton the inaugural head of “the newly created Department of 
Biological Engineering.”112  Despite the farsightedness of its founders, 
the Department changed its status at MIT several times.  In 1998, the 
successor to the Department became a division of the MIT School of 
Engineering, and in 2005, it reemerged as an independent department.113  
In his 1958 acceptance speech of the Nobel Prize for Medicine, Edward L. 
Tatum offered his vision of how biology might transform itself into 
biological engineering: 
With a more complete understanding of the functioning 
and regulation of gene activity in development and 
differentiation, these processes may be more efficiently 
controlled and regulated, not only to avoid structural or 
                                                 
108 On Protein Synthesis, supra note 47, at 139. 
109 Jacob & Monod, supra note 52, at 354. 
110 JAMES BONNER, THE MOLECULAR BIOLOGY OF DEVELOPMENT 134 (1965). 
111 Bhutkar, supra note 57, at 19, 20. 
112 Gerald L. Zeitlin, Professor Joseph Warren Horton (1889–1967):  Biological Engineer, 13 J. 
MED. BIOGRAPHY, 39, 39 (2005). 
113 Massachusetts Institute of Technology School of Engineering, WIKIPEDIA, 
http://en.wikipedia.org/wiki/Massachusetts_Institute_of_Technology_School_of_Engine
ering (last modified July 2, 2011). 
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metabolic errors in the developing organism, but also to 
produce better organisms. 
 . . . [Understanding the genetic code] may permit the 
improvement of all living organisms by processes which 
we might call biological engineering.114 
In 2005, Drew Endy published a series of suggestions entitled 
Foundations for Engineering Biology, which outlined how biology could 
finally achieve its promise as an engineering discipline.115  He proposed 
three general principles: (1) standardization; (2) decoupling; and (3) 
abstraction.116  Standardization required “the definition, description and 
characterization of the basic biological parts, as well as standard 
conditions that support the use of parts in combination and overall 
system operation.”117  Decoupling would break larger problems into a set 
of discrete and smaller problems that could be solved separately.  Then, 
once its constituent smaller problems had been solved, a larger problem 
could be solved.118  Abstraction would involve separating biological 
engineering problems into hierarchical levels of complexity (“abstraction 
hierarchies”) and then reengineering basic biological structures and 
functions into simpler components.119  Biological engineering would 
produce standard biological parts capable of being combined into more 
complex biological devices, which in turn could be combined into even 
more complex biological systems.120 
Work has already begun on producing biological parts.  The Registry 
of Standard Biological Parts “is a continuously growing collection of 
genetic parts that can be mixed and matched to build synthetic biology 
devices and systems.”121  As of June 22, 2011, the Registry contained 
15,177 genetic parts consisting of deposited DNA sequences.122  
Furthermore, the International Open Facility Advancing Biotechnology 
(“Biofab”) was founded in December 2009 “as the world’s first biological 
design-build facility.”123  Funded by the National Science Foundation, 
                                                 
114 Edward Tatum, A Case History in Biological Research, NOBELPRIZE.ORG (June 30, 2011), 
http://nobelprize.org/nobel_prizes/medicine/laureates/1958/tatum-lecture.html. 
115 DREW ENDY, FOUNDATIONS FOR ENGINEERING BIOLOGY 449–53 (2005). 
116 Id. at 450–52. 
117 Id. at 450. 
118 Id. at 451. 
119 Id. at 451–52. 
120 Id. 
121 REGISTRY OF STANDARD BIOLOGICAL PARTS, http://partsregistry.org/Main_Page (last 
visited June 30, 2011). 
122 Statistics Snapshot, REGISTRY OF STANDARD BIOLOGICAL PARTS, 
http://partsregistry.org/cgi/partsdb/Statistics.cgi (last visited June 30, 2011). 
123 About the Biofab, BIOFAB, http://www.biofab.org/about (last visited June 30, 2011). 
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“[o]nce fully operational the Biofab facility will be capable of producing 
tens of thousands of professionally engineered, high-quality standard 
biological parts each year.”124  Whether called biological engineering or 
synthetic biology, a new kind of biology in which DNA is deliberately 
designed, written, and authored has arrived. 
V.  COPYRIGHT PROTECTION FOR DNA125 
Works of genetic authorship fit within the existing framework of 
copyright law.  Congress does not need to amend the Copyright Act 
itself; rather, courts must recognize that DNA is already copyrightable 
subject matter.  In part, this testifies to the flexibility of the Copyright Act 
itself.  However, DNA is also a molecule with properties that uniquely 
preadapt it to eligibility for copyright protection.  It is composed of an 
alphabet of nucleotides, A, G, T, and C, whose specific order creates 
meaning in a polynucleotide sequence.126  The meaning that resides in 
the order of nucleotides is information that is easily decipherable both to 
the cells that harbor DNA and to human readers of nucleotide 
sequences. 
Sequences of DNA have yet to be widely recognized as eligible for 
copyright protection.  This necessitates consideration of several aspects 
of copyright law that might seem to be hurdles for DNA.  These include 
the requirements of statutory subject matter, originality, authorship, and 
expression.  In addition, there are necessary review bars to copyright 
eligibility, such as functionality.  Some of the information in DNA is 
indeed functional.  Nevertheless, due to redundancy in the genetic code 
and to stretches of apparently “junk” DNA, much opportunity exists for 
meaning—and expression—outside of the context of function.  The case 
for DNA copyright, despite functionality, is bolstered by the eligibility of 
computer software for copyright protection because of similarities 
between DNA sequences and computer algorithms, such as their ability 
to encode functions.  Sequences of DNA, especially synthetic DNA, 
                                                 
124 Id. 
125 See infra Part IV (expanding upon the discussion of DNA Copyright in Andrew W. 
Torrance, Synthesizing Law for Synthetic Biology, supra note 1, at 642–48). 
126 RNA is a biological molecule very similar to DNA.  Instead of A, C, G, and T, RNA is 
composed of A, C, G, and uracil (“U”).  Although RNA sometimes forms the genome of 
certain viruses, it more commonly acts as a messenger that carries information from DNA 
for the synthesis of polypeptides (that is, messenger RNA (“mRNA”)), carries amino acids 
to the site of polypeptide synthesis (transfer RNA (“tRNA”)), forms ribosomes (ribosomal 
RNA (“rRNA”)), or resides in the cell nucleus (small nuclear RNA (“snRNA”)).  The case 
for copyright protection of RNA and amino acid sequences is very similar to that for DNA.  
In the absence of specific differences, this article will use “DNA” as a shorthand for DNA, 
RNA, and polypeptides. 
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already fit within the eligibility requirements of the Copyright Act.  
Recognition of this is the next step. 
If recognized, copyright protection may offer an alternative to patent 
protection.  For example, copyright protection is capable of producing a 
socially desirable balance of restricted and permissible uses of DNA 
sequences.  It achieves this balance by replacing the strict liability regime 
of patent law with the more flexible fair use defense and the fostering of 
a feasible open source regime. 
A. History 
A number of authors have already discussed the applicability of 
copyright law to DNA sequences.127  Irving Kayton was the first to 
address the issue in 1982.  Initially, he assumed that DNA was 
uncopyrightable.  As he described, “every intellectual and emotional 
prejudice, both sophisticated and primitive, to which he is subject 
opposed coming to the conclusions finally reached.  Copyright 
protection for engineered DNA sequences seemed ludicrous.”128  Yet, 
careful analysis of the Copyright Act changed his mind decisively.  
Kayton summarized his conclusions as follows: 
virtually all original works of a genetic scientist are 
copyrighted automatically when he creates them; the 
scientist generally can enforce his copyrights; those 
copyrights may provide more effective protection than 
other forms of intellectual property in many 
circumstances; and copyright protection for genetically 
engineered works appears within the constitutional 
limits on Congressional power.129 
Writing later in the decade, and with the benefit of a fuller flowering of 
the biotechnology industry, Dan Burk also came to the conclusion that 
DNA constituted subject matter eligible for copyright protection.  Burk 
suggested that copyright protection could extend “to encompass both 
sequences of nucleotide bases and their written representation.”130  
                                                 
127 E.g., Burk, supra note 7, at 469; Tani Chen, Can a Biological Sequence Be Copyrighted?, 
INTELL. PROP. & TECH. L.J., Mar. 2007, at 1; Duncan M. Davidson, Common Law, Uncommon 
Software, 47 U. PITT. L. REV. 1037, 1104–05 (1986); Kayton, supra note 6, at 191; Smith, supra 
note 7, at 1096–1108; James G. Silva, Copyright Protection of Biotechnology Works:  Into the 
Dustbin of History?, B.C. INTELL. PROP. & TECH. F. (Jan. 28, 2000), http://www.bc.edu/ 
bc_org/avp/law/st_org/iptf/articles/content/2000012801.html. 
128 Kayton, supra note 6, at 218. 
129 Id. at 192. 
130 Burk, supra note 7, at 496. 
Torrance: DNA Copyright
Produced by The Berkeley Electronic Press, 2011
28 VALPARAISO UNIVERSITY LAW REVIEW [Vol. 46 
Although not all analyses have supported the desirability of copyright 
protection for DNA, none of the authors to consider this issue have 
refuted its eligibility under the Copyright Act.  Rather, these analyses 
have tended to reject DNA copyrightability on grounds that either:  (1) 
the DNA sequences in question were natural in origin, and, thus, lacked 
proper authorship or originality; or (2) public policy considerations, 
rather than existing copyright law, militated against protection.  
Furthermore, these previous analyses have not had the opportunity to 
consider the impact of the recent field of synthetic biology, a field based 
on the de novo design and construction of DNA under the direction of 
human creativity.  Where non-synthesized DNA may often be copyright 
eligible, the arguments for copyright protection of synthetic DNA 
sequences are a fortiori. 
B. Requirements 
Copyright protection applies to “original works of authorship fixed 
in any tangible medium of expression, now known or later developed, 
from which they can be perceived, reproduced, or otherwise 
communicated, either directly or with the aid of a machine or device.”131  
Fixation can occur in any “form, manner, or medium.”132  However, the 
mode of fixation must be “sufficiently permanent or stable to permit it to 
be perceived, reproduced, or otherwise communicated for a period of 
more than transitory duration.”133  Since DNA is composed of stable 
chemical nucleotides, DNA sequences should easily meet this 
requirement.  Furthermore, DNA possesses definite sequences of 
nucleotides that can easily be determined,134 copies of DNA may be 
synthesized routinely and in effectively unlimited quantities,135 and 
molecular DNA has been known to last for at least many thousands of 
years with its nucleotide sequence intact.136  The authorship requirement 
might pose a barrier to the copyrightability of genes and other DNA 
sequences derived entirely from natural genomes.  A challenge would be 
posed by 17 U.S.C. § 102, which provides that “[c]opyright protection 
subsists . . . in original works of authorship.”137  By analogy, someone 
                                                 
131 17 U.S.C. § 102 (2006). 
132 H.R. REP. NO. 94-1476, at 52 (1976). 
133 17 U.S.C. § 101 (2006). 
134 See, e.g., F. Sanger et al., DNA Sequencing with Chain-Terminating Inhibitors, 74 PROC. 
NAT’L ACAD. SCI. U.S.A. 5463 (1977). 
135 See, e.g., 2 JOSEPH SAMBROOK & DAVID W. RUSSELL, MOLECULAR CLONING:  A 
LABORATORY MANUAL 8.4 (3d ed. 2001). 
136 See, e.g., Eske Willerslev & Alan Cooper, Ancient DNA, 272 PROC. ROYAL SOC’Y B. 3, 3–
5 (2005). 
137 17 U.S.C. § 102 (2006). 
Valparaiso University Law Review, Vol. 46, No. 1 [2011], Art. 1
https://scholar.valpo.edu/vulr/vol46/iss1/1
2011] DNA Copyright 29 
other than the author could not claim copyright protection for a 
preexisting manuscript simply by discovering its existence.138  However, 
synthetic biology can involve the design and construction of new, 
human-designed DNA sequences.  Here the synthetic biologist designs 
the particular DNA sequence and “writes” it when she synthesizes it.139  
Since there is an author in this case, such DNA sequences should qualify 
as “original works of authorship.”  Furthermore, although DNA 
sequences lack the explicit statutory recognition as copyrightable subject 
matter that computer software possesses, synthetic DNA sequences 
should be eligible for copyright protection under the expansive 
interpretation of “works of authorship” manifested by Congress in the 
legislative history of the 1976 amendments to the Copyright Act.140  
Finally, DNA sequences can be “perceived, reproduced, or otherwise 
communicated, either directly or with the aid of a machine or device.”141  
The genetic code of DNA is well understood by biologists, and DNA 
sequences are easily reproduced.142  Furthermore, machines and routine 
laboratory methods allow the specific nucleotides in DNA sequences to 
be determined.143 
Originality is another requirement of copyrightability.  All sequences 
of DNA are composed of existing nucleotides, each of which is 
individually not new.  Some DNA sequences are “recombinant” 
assemblages of existing nucleotide sequences ligated together.  If the 
focus of analysis were individual nucleotides or constituent sequences, 
originality of DNA might be in question.  However, in Roth Greeting 
Cards v. United Greeting Cards Co., an analogous case of greeting cards 
                                                 
138 Of course, non-authors may obtain copyright protection through contractual means 
for works authored by others. 
139 In fact, fixing a DNA sequence via more conventional tangible forms of expression, 
such as writing the nucleotide sequence down on paper, may also suffice. 
140 See H.R. REP. NO. 94-1476, at 51 (1976) (describing the history of expansively 
interpreting “works of authorship” to include new and varied forms of information). 
The history of copyright law has been one of gradual expansion in the 
types of works accorded protection, and the subject matter affected by 
this expansion has fallen into two general categories.  In the first, 
scientific discoveries and technological developments have made 
possible new forms of creative expression that never existed before.  In 
some of these cases the new expressive forms—electronic music, 
filmstrips, and computer programs, for example—could be regarded 
as an extension of copyrightable subject matter Congress had already 
intended to protect, and were thus considered copyrightable from the 
outset without the need of new legislation. 
Id. 
141 17 U.S.C. § 102. 
142 See, e.g., SAMBROOK & RUSSELL, supra note 135, at 8.4–8.17. 
143 See, e.g., Sanger et al., supra note 134, at 5463. 
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whose constituent parts were not new, the court pointed out that the 
“proper analysis of the problem requires that all elements of each 
[work] . . . be considered as a whole. . . . Considering all of these 
elements together, the Roth cards are, in our opinion, both original and 
copyrightable.”144  Like greeting cards, recombinant or fully-synthetic 
DNA sequences should be considered as a whole.  Under this 
perspective, recombinant or synthetic DNA sequences are also likely to 
qualify as original.  Furthermore, novel nucleotides can also be used to 
make nucleotide sequences.  In 2011, geneticists Farren Isaacs, George 
Church, and others developed a method of creating organisms with 
genetic codes different from those of existing organisms.145  Thus, not 
only can synthetic biology create DNA sequences never before seen 
outside the laboratory, entirely new genetic codes can be developed as 
alternatives to existing codes based on DNA or RNA. 
C. Subject Matter 
There is no explicit mention of DNA sequences in 17 U.S.C. § 102, 
nor do any of the eight enumerated categories of copyrightable subject 
matter explicitly include DNA sequences.  There are, however, several 
significant respects in which DNA, genes, arrays of genes, and genomes 
(not to mention their RNA and polypeptide products) fit within the 
“literary works” category,146 both generally and as computer programs.  
Like the English alphabet of twenty-six letters, DNA is composed of an 
alphabet of four nucleotide “letters”:  A, T, G, and C.147  Triplets of these 
nucleotide letters form “codons” that correspond to specific amino acids.  
When strung together in a linear chain, amino acids comprise 
polypeptides.  A synthetic biologist can “write” strings of nucleotides 
(for example, genes) in any pattern she wishes.  Some patterns of 
nucleotide letters could be written to produce specifically desired linear 
chains of amino acids.  At a higher level of organization, a synthetic 
biologist could compose arrays of multiple synthetic genes in particular 
patterns to produce complex results inside and outside of cells.  Literary 
works are defined in § 101 as “works . . . expressed in words, numbers, 
                                                 
144 429 F.2d 1106, 1109 (9th Cir. 1970).  This case relied on the Copyright Act of 1909 and 
was therefore superseded by the new Copyright Act.  See Loree Rodkin Mgmt. Corp. v. 
Ross-Simons, Inc., 315 F. Supp. 2d 1053, 1055 n.1 (C.D. Cal. 2004) (explaining that Ross did 
not control that case because Ross relied on the 1909 Copyright Act which was amended by 
the Copyright Act of 1976). 
145 Farren J. Issacs et al., Precise Manipulation of Chromosomes in Vivo Enables Genome-Wide 
Codon Replacement, 333 SCI. 348, 348353 (2011). 
146 17 U.S.C. § 102 (2006). 
147 A similar molecule, RNA, is composed of adenine, uracil (instead of thymine), 
guanine, and cytosine.  The RNA alphabet is A, U, G, and C. 
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or other verbal or numerical symbols or indicia, regardless of the nature 
of the material objects . . . in which they are embodied.”148  Nucleotides, 
DNA, RNA, genes, amino acids, polypeptides, and proteins are certainly 
“indicia,” and the letters used to denote nucleotides and amino acids, as 
well as the codes used to denote genes may also qualify as 
“verbal . . . symbols.”149  Furthermore, the statement “regardless of the 
nature of the material objects . . . in which they are embodied” could 
certainly include DNA or its related molecules.150 
Eligibility for copyright protection is not restricted to the seven 
enumerated categories under § 102.  Rather, the section introduces the 
enumerated categories with the phrase “include[s] the following 
categories.”151  In the “Definitions” section of the Copyright Act, § 101 
explains that the “term[ ] ‘including’ . . . [is] illustrative and not 
limitative.”152  The House Report accompanying the 1976 Copyright Act 
reinforces this broad interpretation: 
The use of the word “include,” as defined in [§] 101, 
makes clear that the listing is “illustrative and not 
limitative,” and that the seven categories do not 
necessarily exhaust the scope of “original works of 
authorship” that the bill is intended to protect.  Rather, 
the list sets out the general area of copyrightable subject 
matter, but with sufficient flexibility to free the courts 
from rigid or outmoded concepts of the scope of 
particular categories.153 
When considered in conjunction with the expansive phrase in § 102, 
“any tangible medium of expression, now known or later developed,”154 
synthetic DNA sequences fit comfortably within the category of “literary 
works.”155 
D. Software 
In 1974, the National Commission on New Technological Uses of 
Copyrighted Works (“CONTU”) issued a report concluding that 
“computer programs, to the extent that they embody an author’s original 
                                                 
148 17 U.S.C. § 101 (2006). 
149 Id. 
150 Id. 
151 17 U.S.C. § 102. 
152 17 U.S.C. § 101. 
153 See H.R. REP. NO. 94-1476, at 53 (1976). 
154 17 U.S.C. § 102. 
155 Id. 
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creation, are proper subject matter of copyright.”156  The CONTU was 
careful to distinguish copyrightable subject matter, such as creative 
expression in computer software, from uncopyrightable subject matter, 
such as “idea[s], procedure[s], process[es], system[s], method[s] of 
operation, concept[s], principle[s], or discover[ies].”157  Moreover, it 
emphasized that “one is always free to make the machine do the same 
thing as it would if it had the copyrighted work placed in it, but only by 
one’s own creative effort rather than by piracy.”158  Formal recognition of 
computer software as copyrightable subject matter occurred in 1980, 
when Title 17 (the “Copyright Act”) was amended to include explicit 
copyright protection for computer software.159  Section 101 of the 
Copyright Act defines “computer program” as “a set of statements or 
instructions to be used directly or indirectly in a computer in order to 
bring about a certain result.”160  Although there are some special 
limitations on the exclusive rights conferred to owners of copyrights on 
computer software,161 this form of expression is now routinely protected 
by copyright. 
Synthetic biology is largely based on a conception of genes, cells, and 
organisms as programmable.  In a measured version of this conception, 
Endy has suggested that “synthetic biology provides an opportunity to 
test the hypothesis that the genomes encoding natural biological systems 
can be ‘re-written,’ producing engineered surrogates that might usefully 
supplant some natural biological systems.”162  However, as a more 
ambitious articulation has portrayed it, “[a] primary objective of 
[synthetic biology] is to create a programmable microorganism from 
scratch,” 163 and it is increasingly possible to “program living organisms 
in the same way a computer scientist can program a computer.”164  
Consequently, if computer software is copyrightable, perhaps “biological 
software” is, or ought to be, as well. 
It is relatively easy for a human mind to understand the “meaning” 
of a DNA sequence.  Once a proper reading frame has been determined 
                                                 
156 NAT’L COMM’N ON NEW TECHNOLOGICAL USES OF COPYRIGHTED WORKS, FINAL REPORT 
OF THE NATIONAL COMMISSION ON NEW TECHNOLOGICAL USES OF COPYRIGHTED WORKS 1, 2 
(1978) [hereinafter NAT’L COMM’N]. 
157 Id. at 18 (citing 17 U.S.C. § 102 (b)). 
158 Id. at 21. 
159 See H.R. REP. NO. 96-1307, pt. 1, at 23–24 (1980). 
160 17 U.S.C. § 101 (2006). 
161 17 U.S.C. § 117 (2006). 
162 ENDY, supra note 115, at 449. 
163 Bhutkar, supra note 57, at 20. 
164 D.I.Y. Organisms, ECOPOLIS, http://www.ecopolis.org/diy-organisms/ (last visited 
July 17, 2011). 
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for the sequence,165 one only has to recognize triplets of nucleotides and 
assign corresponding amino acids to each triplet.  Thus, someone of 
modest skill in genetics could examine a DNA sequence of 300 coding 
nucleotides, in proper reading frame, and then determine the specific 100 
amino acid sequence of its corresponding polypeptide.  By contrast, it is 
much more difficult for one of similar skill in computer software to 
understand the “meaning” of either object code or source code.  With 
respect to computer software, both source code and object code are 
eligible for copyright protection.166  Source code is a form of a computer 
program expressed in a programming language understandable to 
humans.  Object code, by contrast, is a form of a computer program 
expressed in binary (that is, “1s” and “0s”); object code cannot generally 
be understood by the human mind.  If object code is eligible for 
copyright protection, then, a fortiori, so should DNA sequences because 
they can be relatively easily understood. 
Rather than portray DNA sequences as analogous to computer 
software, a synthetic biologist (and copyright law) might actually 
consider DNA sequences to be a form of computer software.  A gene is a 
set of instructions for producing a polypeptide.167  A cell (or even an 
organism), via the molecules, metabolic pathways, and signaling 
pathways it contains, acts in response to the set of instructions encoded 
in its genes to carry out a certain result.  Thus, “a [gene encodes a] set of 
statements or instructions to be used directly or indirectly in a [cellular] 
computer in order to bring about a certain [metabolic or signaling] 
result.”168  Given that one of the primary goals of synthetic biology is to 
engineer cells and genes to become ever more like computers and 
computer software, as synthetic biology succeeds in making DNA 
appear more similar to computer software, DNA sequences will likely 
move towards copyrightability by analogy to computer software.  
                                                 
165 LEWIN, supra note 15, at 860. 
A reading frame is one of three possible ways of reading a nucleotide 
sequence.  Each reading frame divides the sequence into a series of 
successive triplets.  There are three possible reading frames in any 
sequence, depending on the starting point.  If the first frame starts at 
position 1, the second frame starts at position 2, and the third frame 
starts at position 3. 
Id. 
166 E.g., Apple Computer, Inc. v. Franklin Computer Corp., 714 F.2d 1240, 1248 (3d Cir. 
1983). 
167 LEWIN, supra note 15, at 852.  “A gene is the segment of DNA specifying a polypeptide 
chain.”  Id. 
168 Cf. 17 U.S.C. § 101 (2006) (showing how material about DNA sequences can fit into the 
existing definition of computer software). The bracketed material is added to make this 
point. 
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Alternatively, if cells and organisms are already computers, and genes 
are already software, then DNA sequences are already eligible for 
copyright protection. 
Whether or not cells are computers and genes are computer software 
is largely an empirical question.  Endy offers a number of examples, 
including: 
[a] DNA sequence that programmes a biofilm to take a 
photograph and perform distributed edge-detection on 
the light-encoded image . . . [a] DNA sequence that 
programmes any mammalian cell to count up to 256 in 
response to a generic input signal . . . [and a] DNA 
sequence that programmes any prokaryote to produce 
25 gl-1 artemisinic acid.169 
However, rather than characterizing any of these examples as science 
fiction or hopeful thinking, Endy notes that “each application is 
physically plausible, or is the direct extension of an already 
demonstrated result.”170  This suggests that synthetic biology is well on 
the way towards cells as computers and genes as computer software.  
The consequences for the copyrightability of synthetic DNA sequences 
are significant. 
E. Functionality 
Copyright law limits protection to works of authorship that do not 
monopolize a particular function.171  If a DNA sequence of a synthetic 
gene were to represent the only way of producing an RNA or 
polypeptide with a particular function, then that sequence would not 
likely possess strong copyright protection.  However, if multiple DNA 
sequences could produce the same RNA or polypeptide with a particular 
function, then any one individual sequence would likely have much 
stronger copyright protection.  In addition, as long as a work of 
authorship is original, it cannot infringe the copyright of another work of 
authorship, even if the two works of authorship are identical.  Thus, 
even a copyright protecting a particular synthetic DNA sequence would 
not prevent others from independently designing an identical or similar 
DNA sequence.  As a consequence, independent invention of identical or 
similar synthetic DNA sequences would act as a counterbalance to any 
                                                 
169 ENDY, supra note 115, at 449. 
170 Id. 
171 See 2 MELVILLE B. NIMMER & DAVID NIMMER, NIMMER ON COPYRIGHT § 2.01[A] 
(Matthew Bender, rev. ed., 2009). 
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monopoly rights conferred on the first author.  Copying would still 
constitute copyright infringement, but independent invention would be 
permissible.  This would stand in stark contrast to the rights conferred 
by patents claiming DNA sequences because the strict liability regime of 
patent law does not relieve independent inventors from liability. 
Patent law offers protection for functional creations.  In fact, patent 
law includes an explicit requirement that an invention possess utility in 
order to be eligible for protection with a utility patent.172  By contrast, 
courts have often hesitated to confer copyright protection to utilitarian 
works.  In Baker v. Selden, the Supreme Court refused to endorse 
copyright protection for an accounting system explained in an otherwise 
copyrightable book entitled Selden’s Condensed Ledger of Bookkeeping 
Simplified.173  In explaining why the blank forms in the book were 
ineligible for copyright protection, the court stated that, “in using the 
[accounting system], the ruled lines and headings of accounts [on the 
blank forms] must necessarily be used as incident to it.”174  In other 
words, a work whose form is dictated solely by function is 
uncopyrightable.  However, the mere fact that a work possesses 
functionality does not preclude it from copyright eligibility.  To illustrate 
this point, the book at issue in Baker v. Seldon was copyrightable.  As long 
as a work possesses adequate expression, it is eligible for copyright 
protection—even if it possesses functionality.  Thus, DNA molecules are 
copyrightable to the extent their nucleotide sequences are not dictated by 
function.  If the expression of an idea in an otherwise copyright-eligible 
work is entirely determined by functional considerations, copyright 
protection is not appropriate because expression and idea may have 
impermissibly merged.  Some of the information in DNA is indeed 
functional, but due to redundancy in the genetic code and to stretches of 
apparently “junk” DNA, much opportunity exists for meaning—and 
expression—outside of the context of function.  This may be especially 
true for synthetic DNA sequences.  Synthesized strands of DNA may be 
deliberately designed to lack function.175  They may be designed with 
                                                 
172 35 U.S.C. § 101 (2006). 
173 Baker v. Selden, 101 U.S. 99, 100–01 (1880). 
174 Id. at 104. 
175 Press Release, J. Craig Venter Inst., First Self-Replicating Synthetic Bacterial Cell (May 
20, 2010), available at http://www.jcvi.org/cms/press/press-releases/fulltext/article/first-
self-replicating-synthetic-bacterial-cell-constructed-by-j-craig-venterinstitute-researcher/.  
For commentary of Venter’s breakthrough, see Daniel G. Gibson et al., Creation of a Bacterial 
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function in mind, but may be expressed in many different permutations 
of specific nucleotides and corresponding amino acids.  Additionally, 
some of their nucleotide positions (e.g., the first codon position) may be 
fixed for reasons of function, while other nucleotides (e.g., the second 
and third codon positions) are largely unfettered from functional 
constraints.  Furthermore, even functionality is not an absolute bar to 
copyrightability for DNA sequences or other works.  In fact, the 
functionality threshold a nucleotide sequence must exceed to be eligible 
for copyright protection is not high.  Although some DNA molecules 
whose sequences are strictly functionally constrained may not surmount 
this threshold, many other less-constrained DNA molecules will not be 
precluded from copyrightability on grounds of functionality. 
In practical terms, very short sequences of DNA encoding very short 
polypeptides would probably be uncopyrightable due to the very limited 
number of sequences capable of encoding the corresponding amino 
acids.  Such sequences would likely lack sufficient expression for 
copyrightability.  Such a limitation on copyrightability would ensure 
that short building-block sequences of DNA remained in the public 
domain.  To illustrate, this might cast doubt on the strength of copyright 
protection that Illumina can expect for its oligonucleotides.176  As DNA 
sequences increase in length and complexity, however, their eligibility 
for copyright protection would grow in proportion to their potential to 
be expressed in multiple ways.177  Furthermore, DNA sequences having 
little or no functionality and abundant expression, such as the “Shotgun 
Wedding” puzzle in the 2005 MIT Mystery Hunt, would be readily 
eligible for copyright protection.  Synthetic DNA would be relatively 
more likely than genomic DNA to qualify for copyright protection 
                                                                                                             
L. REV. 1387, 139293 (2011); Thomas H. Murray, What Synthetic Genomes Mean for our 
Future:  Technology, Ethics, and Law, Interests and Identities, 45 VAL. U. L. REV. 1315, 1321, 
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176 See supra Part I (explaining the potential of DNA copyright protection). 
177 Burk, supra note 7, at 501.  Dan Burk uses the example of relatively unconstrained 
“enhancer control sequence,” observing that “[i]n the case of enhancers, the same function 
may be achieved through many arrangements, and thus a particular arrangement may be 
copyrightable.”  Id.  In a footnote to this sentence, Burk adds: 
A closer question may be presented where elements are not absolutely 
constrained by functional considerations, but simply arranged for the 
sake of efficiency.  If only one or a few arrangements are most efficient, 
merger may again prevent their copyrightablility.  Naturally, these 
would be the arrangements innovators would most want to protect. 
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because of its origin within a human design milieu rich in opportunities 
for expressive choices.178 
F. Duration 
A copyright term lasts substantially longer than a patent term.  A 
valid patent only lasts from the date it was issued until 20 years from the 
United States filing date of its corresponding patent application.179  For 
most works of authorship created on or after January 1, 1978, the 
copyright term for an individual author may last throughout the life of 
that author plus 70 additional years,180 while the term for anonymous 
and pseudonymous works and works for hire last for the earlier of 75 
years from publication or 100 years from creation.181  The longer term of 
a DNA copyright would increase the value of this right to its owner.  
However, any deadweight loss caused by this monopoly right would 
create long-term costs to society.  Several features of copyright law 
would act to lessen this burden, such as independent creation, fair use, 
and the opportunities DNA copyright would create for open source 
biology. 
G. Independent Creation 
Unlike the case in patent law, copyright law frees from liability 
independently created works, which are identical to copyrighted works.  
Copyright law simply requires independent creation.182  As long as a 
work authored second in time is original and not copied, it does not 
infringe an identical work created first in time.  In fact, both works 
would qualify for copyright protection.  By contrast, even independently 
created inventions can infringe a patent under the prevailing regime of 
strict liability. 
H. Fair Use 
Unlike patent law, which applies a strict liability standard to 
instances of infringement offering few and insubstantial exceptions, 
                                                 
178 Note that DNA sequences generated by computer software and lacking expressive 
choices would have relatively less eligibility for copyright protection. 
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copyright law includes a provision that explicitly allows several 
significant uses of copyrighted works without resulting in liability for 
infringement.  Section 107 of the Copyright Act, entitled “Limitations on 
exclusive rights:  Fair use,” describes this safe harbor from copyright 
infringement.183  It states: 
the fair use of a copyrighted work, including such use by 
reproduction in copies or phonorecords or by any other 
means specified by [§ 106 and § 106A], for purposes 
such as criticism, comment, news reporting, teaching 
(including multiple copies for classroom use), 
scholarship, or research, is not an infringement of 
copyright.184 
Several of these enumerated instances of fair use are highly relevant to 
DNA sequences.  Section 107 would appear to contemplate the copying 
and use of copyrighted DNA sequences for educational purposes.  For 
example, biology professors and their students would seem permitted to 
make “multiple copies” of copyrighted DNA sequences for use in their 
studies of genetics in their classrooms and teaching laboratories.  In 
addition, scholars and researchers of genetics would appear to be able to 
make and use copies of DNA sequences without triggering liability for 
copyright infringement.  For example, a geneticist could seemingly copy 
and use copyrighted genes for her research, while, by contrast, such 
activities would trigger strict liability under patent law if the genes in 
question were claimed in a patent. 
In addition to enumerated examples of copying that would not 
constitute copyright infringement, § 107 requires a mandatory analysis of 
four factors to determine “whether the use made of a work in any 
particular case is a fair use.”185  These four factors are: 
(1) the purpose and character of the use, including 
whether such use is of a commercial nature or is for 
nonprofit education purposes; 
(2) the nature of the copyrighted work; 
(3) the amount and substantiality of the portion used in 
relation to the copyrighted work as a whole; and 
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(4) the effect of the use upon the potential market for or 
value of the copyrighted work.186 
The relatively stronger case for fair use tends to occur when the copying 
of the work is only partial and the context is noncommercial.  Examples 
might include when copyrighted DNA sequences are used 
transformatively in scholarship or the DNA sequences are copied during 
academic laboratory research.  Alternatively, the relatively weaker case 
for fair use tends to occur when the copying of the work is complete and 
the context is commercial.  Examples might include the wholesale 
representation of complete nucleotide sequences of copyrighted DNA 
molecules on a commercial website or the industrial replication of 
copyrighted DNA sequences for sale at a profit. 
Another exception to copyright infringement can be found in § 108, 
which allows libraries and archives to make and lend a copy of a DNA 
sequence as long as it is done in accordance with the other provisions of 
the section.187 
Patent law allows very few instances of copying to escape 
infringement liability.  Even the use of patented inventions in the 
educational or research environments of universities can trigger patent 
infringement.188  This strict liability regime may chill even 
noncommercial activities, such as academic research, that would seem to 
pose minimal economic threat to owners of patent rights.  The fair use 
defense in copyright creates a significant safe harbor within which 
socially valuable activities, such as academic research, may survive and 
perhaps, even thrive.  Many critics and scientists who consider current 
patent law too unforgiving to genetic research would welcome a 
copyright regime with a robust fair use exception to infringement. 
I. Open Source Biology 
Open source software has generated many valuable innovations.  
These include Linux operating systems, Apache server software, and 
Ruby on Rails database software.  Much open source software is created 
under the rubric of an open source license that relies on copyright law to 
enforce its provisions.  Though often proposed, open source biology has 
thus far failed to make much of an impact on the field of biology.  In 
part, the failure of open source biology can be blamed on the difficulty of 
adapting the patent system to an open source license.  Unless all patent 
rights are covered by an open source license—a virtual impossibility—
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open source biology developers will fear the existence of patent liability 
for their activities.  However, were DNA sequences to be protected by 
copyright rather than patent law, open source licenses could potentially 
offer the same advantages to open source biology as they do to open 
source software.  If synthetic biology were indeed to make it technically 
feasible to develop programmable genes and organisms, open source 
biology licenses undergirded by copyright for DNA sequences could 
help the field achieve its potential. 
VI.  CONCLUSION 
Copyright law has traditionally afforded protection to works of 
authorship such as books, magazines, photographs, paintings, music, 
and sculpture.  The Copyright Act has proved admirably flexible at 
accommodating novel categories of authorship, specifically 
contemplating future developments by covering “original works of 
authorship fixed in any tangible medium of expression, now known or 
later developed.”189  This has led to explicit copyright protection for 
nontraditional works of architecture and computer software.  Sequences 
of DNA should also be acknowledged as eligible for copyright 
protection. 
Unaltered genomic DNA sequences would seem poor candidates for 
copyright protection.  The case is stronger for copyright protection of 
recombinant DNA sequences.  Strongest is the case for the copyright 
eligibility of synthetic DNA sequences designed nucleotide by 
nucleotide and chemically constructed de novo.  Whereas DNA copyright 
has previously remained a largely hypothetical prospect, advances in 
synthetic biology may now force recognition of copyright protection as 
an alternative (or complement) to patent protection. 
A DNA copyright regime would differ substantially from the current 
DNA patent regime.  Notably, acquiring copyright protection for DNA 
would be less expensive and much more rapid than pursuing patent 
protection.  As patent law recognizes few and weak exceptions to 
infringement, copyright law offers a robust fair use exception for 
copying done in contexts such as scholarship and research.  Furthermore, 
copyright protection would be limited in the case of DNA molecules 
whose structures are dictated by functional constraints, thus providing 
the public greater and salutary access to useful genes. 
Copyright protection for DNA lies pregnant within current 
copyright law.  What is required is an effort to make use of the existing 
protection.  A DNA copyright regime would not only allow a more 
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robust set of safe harbors for use of particular DNA sequences, especially 
in genetic research, it would also facilitate the possibility of an open 
source biology movement.  Finally, just as the prospects of patent 
protection for at least some forms of DNA have become uncertain, 
copyright protection could fill any resulting gap by affording a 
reasonable level of intellectual property protection, while simultaneously 
allowing society to enjoy some of the benefits of genetic knowledge more 
freely than the current patent protection is able to afford. 
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